Theralink announces groundbreaking RPPA study by partner GMU – reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Golden, Colorado & Nashville, Tennessee, Dec. 18, 2023 (GLOBE NEWSWIRE) — Theralink Technologies (OTC: THER), a precision oncology company with an exclusively licensed commercial RPPA (reverse phase protein array) technology platform, is excited to announce groundbreaking work by George Mason University and the University of California, San Francisco, recently published in Cell Reports Medicine (https://linkinghub.elsevier.com/retrieve/pii/S2666379123005062). This incredible effort coming from the ISPY-2 trial assessed the tumors from over 700 breast cancer patients via RPPA and uncovered new therapeutic options for some of the most challenging breast cancers that are missed entirely by current diagnostic approaches.
Related news for (THER)
- Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
- Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
- Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
- Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer